Tyra Biosciences Inc (TYRA) - Total Assets
Based on the latest financial reports, Tyra Biosciences Inc (TYRA) holds total assets worth $282.61 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tyra Biosciences Inc - Total Assets Trend (2019–2025)
This chart illustrates how Tyra Biosciences Inc's total assets have evolved over time, based on quarterly financial data. Also see Tyra Biosciences Inc market cap and net worth for the company's overall valuation and market capitalisation.
Tyra Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Tyra Biosciences Inc's total assets of $282.61 Million consist of 93.9% current assets and 6.1% non-current assets. Review how much debt does Tyra Biosciences Inc carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Tyra Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Tyra Biosciences Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tyra Biosciences Inc's current assets represent 93.9% of total assets in 2025, an increase from 24.1% in 2019.
- Cash Position: Cash and equivalents constituted 27.4% of total assets in 2025, up from 20.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Tyra Biosciences Inc Competitors by Total Assets
Key competitors of Tyra Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Tyra Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.67 | 23.81 | 91.74 |
| Quick Ratio | 14.67 | 23.81 | 91.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $247.36 Million | $332.87 Million | $139.29 Million |
Tyra Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Tyra Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.23 |
| Latest Market Cap to Assets Ratio | 4.85 |
| Asset Growth Rate (YoY) | -22.3% |
| Total Assets | $282.61 Million |
| Market Capitalization | $1.37 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Tyra Biosciences Inc's assets at a significant premium (4.85x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Tyra Biosciences Inc's assets decreased by 22.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Tyra Biosciences Inc (2019–2025)
The table below shows the annual total assets of Tyra Biosciences Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $282.61 Million | -22.27% |
| 2024-12-31 | $363.56 Million | +60.97% |
| 2023-12-31 | $225.86 Million | -15.15% |
| 2022-12-31 | $266.18 Million | -13.21% |
| 2021-12-31 | $306.70 Million | +1815.56% |
| 2020-12-31 | $16.01 Million | +2932.39% |
| 2019-12-31 | $528.00K | -- |
About Tyra Biosciences Inc
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. It… Read more